Exhibits

This section begins a sequence of exhibits tied directly to Deepak Chopra - not just by name, but by legal filing, entity, control, and physical address. Multiple business registrations list him or his trusts as a managing party, many of them tied to the 411 E Bonneville Ave, the same address that appears on my paystub. These are one-offs - they are part of a repeating pattern of shell entities and trusts-controlled companies appearing across the country.
There are two individuals named Deepak Chopra active in the wellness and supplement space. However, due to connections like Exhibit 46, which includes the name of the famous Chopra’s wife, and the fact that these entities are deeply interwoven with Sanofi’s network, I have named the well-known Chopra in this arbitration. If discovery later shows it is the other Chopra, I will amend the filing accordingly.

That said, this Chopra has been formally named in the case for over four months. Has offered no denial, no clarification, and no response. And a legal matter of this scale, that silence speaks volumes.

This section marks the introduction of Sanofi — the $120+ billion pharmaceutical giant headquartered at 55 Corporate Drive, Bridgewater, New Jersey. Sanofi ultimately owns Chattem Inc. and Quten, and is directly tied to many of the shell companies, payroll entities, and trusts exposed earlier in this case. QRIB Intermediate Holdings LLC is Quten Research Institute, which is co-founded by Ashraf “Peter” Boutros & Deepak Chopra. Sold to Sanofi in 2023 for $1.4 Billion.

Through complex structuring, Sanofi has kept its name off the front lines, but corporate filings repeatedly link it to the same addresses, the same people, and the same concealment network. Its subsidiaries operate under dissolved or unregistered names, yet continue to issue payroll, marketing directives, and corporate control. These next exhibits begin to show how Sanofi’s clean public image conceals a deeply entangled and legally questionable infrastructure.